← Back to Clinical Trials
Recruiting NCT06277297

NCT06277297 Prognotic Role of CMR in Takotsubo Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06277297
Status Recruiting
Phase
Sponsor University of Cagliari
Condition Takotsubo Cardiomyopathy
Study Type OBSERVATIONAL
Enrollment 350 participants
Start Date 2022-11-09
Primary Completion 2026-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 350 participants in total. It began in 2022-11-09 with a primary completion date of 2026-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary objective of this observational registry is to develop a comprehensive clinical and imaging score (incorporating echocardiography and cardiac magnetic resonance data) that enhances risk stratification for patients with Takotsubo syndrome. The secondary objectives of this registry are as follows: Investigate the diagnostic value of cardiac magnetic resonance parameters in predicting in-hospital and long-term outcomes in patients with Takotsubo syndrome. Compare the proposed risk stratification score for patients with Takotsubo syndrome with previously existing scores. Investigate the contribution of machine learning models in predicting in-hospital and long-term outcomes compared to standard clinical scores. The design and rationale of this registry are available at 10.1097/RTI.0000000000000709

Eligibility Criteria

Inclusion Criteria: * Takotsubo syndrome diagnosis (according to Position Statement of the European Society of Cardiology Heart Failure Association) * Adult patients ( \> 18y old) * Availability at baseline of clinical variables, standard transthoracic echocardiography, and cardiovascular magnetic resonance acquisition Exclusion Criteria: * \<18 y old * Lack of transthoracic echocardiography and cardiovascular magnetic resonance examinations * Preexisting cardiomyopathies * Previous myocardial infarction * Suspected or known prior irreversible myocardial damage * Valvular heart disease

Contact & Investigator

Central Contact

Riccardo Cau, MD

✉ riccardo.cau@unica.it

📞 +3393493317

Frequently Asked Questions

Who can join the NCT06277297 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Takotsubo Cardiomyopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06277297 currently recruiting?

Yes, NCT06277297 is actively recruiting participants. Contact the research team at riccardo.cau@unica.it for enrollment information.

Where is the NCT06277297 trial being conducted?

This trial is being conducted at Cagliari, Italy.

Who is sponsoring the NCT06277297 clinical trial?

NCT06277297 is sponsored by University of Cagliari. The trial plans to enroll 350 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology